The University Medical Center Groningen (UMCG) and SHINE Europe have secured a €10.5 million grant from the Dutch government. The funding, awarded last week, will support the ‘Terbium for Life’ project, aimed at advancing the production of terbium isotopes for cancer theranostics – therapy and diagnostics – in Europe. With global early-onset cancer cases rising by 79%, this initiative promises to enhance treatment capabilities, potentially extending patient lifetimes and reducing side effects. The collaboration aligns with Europe’s Strategic Agenda for Medical Ionising Radiation Applications, offering hope for improved access to innovative cancer therapies.
Terbium-161, the primary isotope in the Terbium for Life project, holds promise for extending patient lifetimes. Alongside Tb-161, other isotopes like Tb-155, Tb-152, and Tb-149 are being explored for their diagnostic and therapeutic applications. This project is a significant step towards enhancing cancer treatment capabilities in Europe and ensuring that patients have access to cutting-edge therapies. The isotopes’ development supports the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA), which guides European advancements in radiological and nuclear technology.
UMCG specializes in nuclear medicine, providing advanced imaging and therapeutic technologies for cancer diagnosis and treatment. SHINE Technologies, headquartered in Janesville, Wisconsin, is a leader in next-generation fusion technology and medical isotope production.
Leadership perspectives
Dr. Philip H. Elsinga, a professor of PET Radiochemistry at UMCG, emphasizes the transformative potential of this collaboration: ‘Our goal is to develop innovative treatments that offer new hope for cancer patients.’ This sentiment is echoed by Harrie Buurlage, VP of Strategic Alliances at SHINE Europe, who expressed gratitude for the grant, highlighting its role in providing European patients with access to promising new therapies. The partnership between UMCG and SHINE Europe is poised to make significant strides in the fight against cancer.
Looking ahead
With the grant secured, the Terbium for Life project is set to make significant contributions to cancer theranostics. By ensuring a steady supply of terbium isotopes, UMCG and SHINE Europe are not only addressing current healthcare needs but also paving the way for future innovations. This initiative promises to transform cancer treatment, offering hope to patients across Europe and beyond. As the project progresses, the collaboration will continue to align with SAMIRA’s objectives, further solidifying Europe’s position in the field of medical ionizing radiation applications.
Related Posts
